Walmart (NYSE:WMT) Partners With Soda Health To Enhance Member Wellness Through Retail Insights
Walmart recently announced a collaboration with Soda Health to launch the Walmart Everyday Health Signals Program, aiming to enhance wellness for Medicare Advantage and Medicaid members. Over the last quarter, Walmart's share price increased by 9%, reflecting the company's efforts to innovate in personalized healthcare solutions alongside a general upward market trend. During the period, key developments, like the national launch of PurSteam Steam Station Max, along with the introduction of sustainable beverage supplies and in-store expansion initiatives, added momentum to Walmart's performance. Meanwhile, legal matters like the Zest Labs verdict and strategic buybacks likely moderated any potential headwinds.
We've discovered 2 weaknesses for Walmart that you should be aware of before investing here.
The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
The collaboration between Walmart and Soda Health to launch the Everyday Health Signals Program could enhance its focus on personalized healthcare, aligning with its expansion into higher-margin ventures like membership, marketplace, and advertising. These initiatives may positively influence Walmart's revenue and earnings forecasts by potentially boosting operational efficiency and customer engagement, though execution risks remain. In terms of share price movement, the recent increase of 9% over the last quarter appears consistent with these strategic moves and broader market trends.
Walmart's shares have achieved a total return of 150.80% over the past five years, showcasing impressive long-term growth. In contrast, over the last year, Walmart's performance slightly lagged behind the US Consumer Retailing industry, which returned an average of 7.80%, with Walmart's one-year return being 6.80%. This suggests that while long-term growth has been robust, recent performance may reflect current operational challenges or competitive pressures within the industry.
The analyst consensus price target for Walmart is US$107.01, representing a 7.90% potential upside from the current share price of US$98.55. Given the company's recent achievements and investments, along with the anticipated enhancements in operational efficiency and revenue streams, the divergence between the current share price and the target may indicate market expectations of continued growth, albeit tempered by existing risks and market conditions. It remains important for investors to evaluate these factors and their alignment with personal investment strategies.
Explore historical data to track Walmart's performance over time in our past results report.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NYSE:WMT.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
擷取數據時發生錯誤
登入存取你的投資組合
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
22 minutes ago
FDA approves the world's only twice-a-year shot to prevent HIV
WASHINGTON -- The U.S. has approved the world's only twice-a-year shot to prevent HIV, maker Gilead Sciences announced Wednesday. It's the first step in an anticipated global rollout that could protect millions – although it's unclear how many in the U.S. and abroad will get access to the powerful new option. While a vaccine to prevent HIV still is needed, some experts say the shot — a drug called lenacapvir — could be the next best thing. It nearly eliminated new infections in two groundbreaking studies of people at high risk, better than daily preventive pills they can forget to take. 'This really has the possibility of ending HIV transmission,' said Greg Millett, public policy director at amfAR, The Foundation for AIDS Research. Condoms help guard against HIV infection if used properly but what's called PrEP — regularly using preventive medicines such as the daily pills or a different shot given every two months — is increasingly important. Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more frequent doctor visits or stigma from daily pills. But upheaval in U.S. healthcare — including cuts to public health agencies and Medicaid — and slashing of American foreign aid to fight HIV are clouding the prospects. Millett said "gaping holes in the system" in the U.S. and globally "are going to make it difficult for us to make sure we not only get lenacapavir into people's bodies but make sure they come back' even as little as twice a year. Gilead's drug already is sold to treat HIV under the brand name Sunlenca. The prevention dose will be sold under a different name, Yeztugo. It's given as two injections under the skin of the abdomen, leaving a small 'depot' of medication to slowly absorb into the body. Gilead didn't immediately announce its price. The drug only prevents HIV transmission – it doesn't block other sexually transmitted diseases. Global efforts at ending the HIV pandemic by 2030 have stalled. There still are more than 30,000 new infections in the U.S. each year and about 1.3 million worldwide. Only about 400,000 Americans already use some form of PrEP, a fraction of those estimated to benefit. A recent study found states with high use of PrEP saw a decrease in HIV infections, while rates continued rising elsewhere. About half of new infections are in women, who often need protection they can use without a partner's knowledge or consent. One rigorous study in South Africa and Uganda compared more than 5,300 sexually active young women and teen girls given twice-yearly lenacapavir or the daily pills. There were no HIV infections in those receiving the shot while about 2% in the comparison group caught HIV from infected sex partners. A second study found the twice-yearly shot nearly as effective in gay men and gender-nonconforming people in the U.S. and in several other countries hard-hit by HIV. Ian Haddock of Houston had tried PrEP off and on since 2015 but he jumped at the chance to participate in the lenacapavir study and continues with the twice-yearly shots as part of the research follow-up. 'Now I forget that I'm on PrEP because I don't have to carry around a pill bottle,' said Haddock, who leads the Normal Anomaly Initiative, a nonprofit serving Black LGBTQ+ communities. 'Men, women, gay, straight – it really just kinds of expands the opportunity for prevention,' he added. Just remembering a clinic visit every six months 'is a powerful tool versus constantly having to talk about, like, condoms, constantly making sure you're taking your pill every day.' 'Everyone in every country who's at risk of HIV needs access to PrEP,' added Dr. Gordon Crofoot of Houston, who helped lead the study in men. 'We need to get easier access to PrEP that's highly effective like this is.'
Time Business News
an hour ago
- Time Business News
Your Step-by-Step Method to Find the Best Drug Rehab for Sale
Before entering the rehab marketplace, clarify the specific attributes you seek in a facility. Define the level of care you wish to provide—whether inpatient residential treatment, intensive outpatient (IOP), detox services, or a continuum of care. Set parameters for ideal location, target patient demographics, payer mix (private pay, Medicaid, commercial insurance), and operational scale. Establish your investment range and financial return goals. This clarity will narrow your search and prevent distractions from opportunities that don't align with your objectives. Investing in a healthcare facility can be a rewarding venture, especially when considering established operations with a proven track record. Buyers seeking a stable and impactful business often look for options that combine community need with financial viability. In the middle of such opportunities, drug rehab for sale listings provide access to facilities already equipped with essential infrastructure, licenses, and a client base. Acquiring an existing center can reduce startup time and risks while offering immediate revenue streams. Careful evaluation of financial health, regulatory compliance, and reputation is crucial to ensure a successful transition and continued positive outcomes. Start by researching regional demand for substance use treatment. Evaluate areas with underserved populations, favorable reimbursement rates, and strong referral networks. Use SAMHSA's Treatment Locator, public health data, and state licensing records to identify geographic gaps. Learn about competitors in your target area and assess how the rehab center you seek can either fill a void or enhance existing care infrastructure. Understanding market dynamics early empowers you to recognize high-potential opportunities. Rehab centers are niche businesses, and general business brokers may lack the expertise to navigate their complexities. Partner with brokers who specialize in behavioral health transactions—they often have access to off-market listings and can provide early access to deals. Additionally, build a team of advisors that includes a healthcare attorney, M&A consultant, and behavioral health accountant. These professionals will help assess opportunities, conduct due diligence, and negotiate with confidence. When evaluating listings, request preliminary information such as profit and loss statements, census data, service lines, licensing status, and payer contracts. Verify that the facility is fully licensed, credentialed with insurers, and in good standing with regulatory bodies. Respect confidentiality—most sellers will require you to sign a non-disclosure agreement (NDA) before sharing detailed information. Analyze performance trends, staff retention, and operational risks to determine if the listing fits your strategic goals. Once a potential fit is identified, begin an exhaustive due diligence process. Review financial records, billing practices, payer reimbursements, clinical documentation, staff contracts, and compliance history. Conduct a site visit to assess the physical condition, community reputation, and leadership team. Confirm licensure transferability and identify any liabilities—legal, regulatory, or reputational. Solid due diligence uncovers risks and allows you to negotiate price and terms accordingly. With a viable candidate in hand, arrange your capital—whether through cash, SBA loans, private equity, or seller financing. Work with your attorney to draft a letter of intent (LOI) outlining purchase price, structure, contingencies, and closing timeline. Once mutually agreed upon, move toward a formal purchase agreement. Make sure post-acquisition transition plans are included, such as staff retention, patient continuity, and brand handover, to ensure a seamless change of ownership. Understanding the financial landscape of behavioral health entities is essential for informed decision-making and sustainable growth. Investors, operators, and stakeholders increasingly rely on detailed assessments to gauge potential and risk. In the middle of these evaluations, behavioral health finance valuation provides a framework for analyzing revenue streams, payer mixes, and cost structures unique to this sector. Accurate valuation not only reflects a company's current position but also influences strategic planning, mergers, and acquisitions. By leveraging industry-specific benchmarks and performance metrics, organizations can better communicate their value, attract capital, and navigate the evolving demands of the healthcare marketplace. Finding the best drug rehab for sale requires diligence, strategic insight, and a team that understands the intricacies of behavioral healthcare. By defining your criteria, researching the market, working with experts, and conducting thorough due diligence, you position yourself to acquire a facility that delivers both clinical impact and financial sustainability. With the right rehab center, you gain more than a business—you take on a mission to transform lives through structured, compassionate care. TIME BUSINESS NEWS
Yahoo
an hour ago
- Yahoo
Chicken fettuccine Alfredo products voluntarily recalled over listeria concerns
Ready-to-eat grilled chicken fettuccine Alfredo products that were sold at Walmart and Kroger have been voluntarily recalled due to possible listeria contamination, the U.S. Department of Agriculture's Food Safety and Inspection Service announced Tuesday. Food manufacturer FreshRealm's establishments in San Clemente, California; Montezuma, Georgia; and Indianapolis, Indiana, are voluntary recalling the prepared pasta dishes because they "may be adulterated with an outbreak strain of Listeria monocytogenes," the FSIS stated. The recalled products may be linked to a multistate outbreak of listeria infections across 13 states that has sickened 17 people and resulted in at least three deaths in Illinois, Michigan and Texas as of this week, according to the Centers for Disease Control and Prevention. One "pregnancy associated illness resulted in a fetal loss," the agency said Wednesday. Three products are affected by the recall. According to FreshRealm, the meals were sold nationwide "at Walmart, under the Marketside brand and Kroger, under the Home Chef brand." The affected products include: 32.8-ounce tray packages containing "MARKETSIDE GRILLED CHICKEN ALFREDO WITH FETTUCCINE Tender Pasta with Creamy Alfredo Sauce, White Meat Chicken and Shaved Parmesan Cheese," with best-by dates of June 27, 2025, or prior. 12.3-ounce tray packages containing "MARKETSIDE GRILLED CHICKEN ALFREDO WITH FETTUCCINE Tender Pasta with Creamy Alfredo Sauce, White Meat Chicken, Broccoli and Shaved Parmesan Cheese," with best-by dates of June 26, 2025, or prior. 12.5-ounce tray packages containing "HOME CHEF Heat & Eat Chicken Fettuccine Alfredo with pasta, grilled white meat chicken, and Parmesan cheese," with best-by dates of June 19, 2025, or prior. The products have a USDA mark of inspection on the label, as well as establishment numbers EST. P-50784, EST. P-47770 or EST. P-47718 printed on the side of the packaging, the FSIS said this week. "FreshRealm has notified Walmart and Kroger to remove this meal from their shelves and inventory. Consumers who have purchased the meal should destroy it or return it to the place of purchase for a refund," FreshRealm stated in a press release Wednesday, adding that the company "remains committed to the highest standards of food safety" and is "working closely" with the Food and Drug Administration, FSIS and CDC "to provide full transparency and access throughout the process." The recall does not apply to any other FreshRealm products, the company said. Consumers with questions about the recall can contact FreshRealm customer service at (888) 244-1562. The outbreak strain of listeria was identified in samples collected from sick individuals between Aug. 1, 2024, and May 27, 2025. State and local public health officials interviewed 11 people about the foods they consumed in the month before they got sick, and seven reported eating pre-cooked meals, with four stating specifically that they had eaten chicken fettucine Alfredo products. The outbreak strain of listeria was isolated from a routine chicken fettuccine Alfredo sample collected by FSIS in a FreshRealm establishment in March 2025. The agency noted that "the lot of chicken fettuccine alfredo represented by this sample was held during sampling, destroyed, and never entered commerce," and "subsequent investigations at the establishment that produced this product, and into the product ingredients, have not identified the source of contamination." In its press release Wednesday, FreshRealm stated that it "has not received any direct reports of illness associated with the product and has received information on cases from the regulatory agencies, including that four consumers have reported eating the chicken alfredo product." "The recalled product has not been established as a cause of any of these cases," the company said. Of the 17 people sickened by the outbreak strain of listeria, 16 were hospitalized. According to the CDC, the "true number of sick people in this outbreak is likely higher than the number reported," and the outbreak "may not have been limited to the states with known illnesses ... because some people recover without medical care and are not tested for Listeria." "In addition, recent illnesses may not yet be reported as it usually takes 3 to 4 weeks to determine if a sick person is part of an outbreak," the CDC stated. Listeria is a bacteria that when ingested can cause an infection known as listeriosis, according to the CDC. The condition is most dangerous for pregnant people, newborns, people with weakened immune systems and adults 65 or older, the agency said. For people who are pregnant, being infected by listeria can cause pregnancy loss or premature birth. According to the CDC, an estimated 1,600 people get listeriosis annually in the U.S. and about 260 people die from it.
